Richard Pzena
Pzena Investment Management
Richard Pzena Sanofi ADR stake
total: 584
Pzena Investment Management SNY trades
- Total transactions:
- 6
- New positions:
- 1
- Added:
- 5
- Held since:
- 2025 Q1
- Held for:
- 6 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Richard Pzena holds 25,302 Sanofi ADR (SNY) shares with a market value of roughly $1.08M accounting for 0.00% of the overall portfolio. To date, the estimated cost basis is nearly $48.39 for "buy" trades. Pzena Investment Management first purchased SNY in 2025 Q1, initially acquiring 5,385 shares. Since the initial investment in Sanofi ADR (SNY), Pzena Investment Management has made 5 more transactions.
When did Richard Pzena buy Sanofi ADR (SNY)?
Richard Pzena first invested in Sanofi ADR (SNY) in 2025 Q1 at the reported quarter-end price of $55.46 per share.
What's the cost basis of Pzena Investment Management's SNY stake?
The estimated cost basis for Sanofi ADR (SNY) stake is around $48.39 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $48.39
Richard Pzena's historical trades in Sanofi ADR
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
25,302
|
$42.66
|
$1,079,391
|
+32.55% (+6,214)
|
+0%
|
|
2026 Q1
|
0.00%
|
19,088
|
$48.18
|
$919,636
|
+62.46% (+7,339)
|
+0%
|
|
2025 Q4
|
0.00%
|
11,749
|
$48.46
|
$569,342
|
+76.25% (+5,083)
|
+0%
|
|
2025 Q3
|
0.00%
|
6,666
|
$47.20
|
$314,624
|
+19.46% (+1,086)
|
+0%
|
|
2025 Q2
|
0.00%
|
5,580
|
$48.31
|
$269,564
|
+3.62% (+195)
|
+0%
|
|
2025 Q1
|
0.00%
|
5,385
|
$55.46
|
$298,679
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.